|
|
Clinical effect of Ceftazidime combined with Levofloxacin in treatment of elderly patients with heart failure complicated with pulmonary infection |
LIU Yanjun1 QI Liwen2 |
1.Department of Pharmacy,Feicheng People′s Hospital,Shandong Province,Feicheng 271600,China;
2.Department of Gastroenterology,Feicheng People′s Hospital,Shandong Province,Feicheng 271600,China |
|
|
Abstract Objective To investigate the clinical effect of Ceftazidime combined with Levofloxacin in the treatment of elderly patients with heart failure complicated with pulmonary infection.Methods Seventy-six elderly patients with heart failure complicated with pulmonary infection who were admitted to Feicheng People′s Hospital from May 2019 to May 2020 were selected as subjects and divided into the observation group and the control group by the random number table method,with 38 patients in each group.All patients were treated with diuresis,cardiac strengthening,vasodilation and other conventional treatment.The control group was treated with Ceftazidime for injection.The observation group was treated with intravenous Levofloxacin on the basis of the control group.The levels of inflammatory factors in the two groups before and after treatment were compared,mainly including the levels of B-type natriuretic peptide(BNP),white blood cell (WBC),procalcitonin (PCT),interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α).Cardiac function indexes of the two groups were compared before and after treatment,and the changes of left ventricular diastolic diameter (LEVDD),left ventricular end systolic diameter (LVESD),left ventricular ejection fraction (LVEF)and end systolic left ventricular diameters (LVDs) were recorded.The clearance of pathogenic bacteria between the two groups was compared,and samples from the two groups were collected before and after treatment to detect the numbers of pathogenic bacteria.The therapeutic effect of the two groups were compared.Results There were no significant differences in the levels of IL-6,TNF-α,BNP,WBC and PCT between the two groups before treatment (P>0.05).The levels of IL-6,TNF-α,BNP,WBC and PCT in observation group were lower than those in control group after treatment,the differences were statistically significant (P<0.05).The levels of IL-6,TNF-α,BNP,WBC and PCT in the two groups after treatment were lower than the those before treatment,the differences were statistically significant (P<0.05).There were no significant differences in cardiac function indexes between the two groups before treatment (P>0.05).After treatment,LVESD,LEVDD and LVDs in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.05).The LVEF of the observation group was higher than that of the control group after treatment,and the difference was statistically significant (P<0.05).The LVESD,LEVDD and LVDs in the two groups after treatment were lower than those before treatment,and the differences were statistically significant (P<0.05).The LVEF levels of the two groups after treatment were higher than those before treatment,and the differences were statistically significant (P<0.05).The clearance rate of pathogenic bacteria in the observation group was higher than that in the control group after treatment,and the difference was statistically significant (P<0.05).The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Ceftazidime combined with Levofloxacin in the treatment of senile heart failure complicated with pulmonary infection has a good therapeutic effect,which has the significance of clinical promotion.
|
|
|
|
|
[1] |
刘庆力,杨丽.头孢他啶联合左氧氟沙星治疗老年患者心力衰竭并发肺部感染的临床观察[J].天津药学,2021,33(4):52-55.
|
[2] |
董学花.头孢他啶和左氧氟沙星联用对呼吸内科感染患者抗感染的临床效果与不良反应发生情况探讨[J].中国实用医药,2021,16(22):144-146.
|
[3] |
闫淑芬.头孢他啶联合左氧氟沙星对心力衰竭合并肺部感染患者炎症因子水平的影响[J].北方药学,2017,14(4):128-129.
|
[4] |
黄春丽.头孢他啶联合左氧氟沙星治疗心力衰竭患者肺部感染的效果分析[J].海峡药学,2020,32(8):124-126.
|
[5] |
顾岩,丁兆军,张润泽.左氧氟沙星结合头孢他啶治疗晚期泌尿系肿瘤感染的效果[J].当代医学,2020,26(7):144-146.
|
[6] |
刘佳.心力衰竭并肺部感染患者应用头孢他啶联合左氧氟沙星治疗的价值探究[J].当代医学,2019,25(35):145-146.
|
[7] |
王燕玲.头孢他啶和左氧氟沙星对心力衰竭伴肺部感染老年患者抗感染治疗的临床疗效评价[J].抗感染药学,2017,14(2):430-432.
|
[8] |
涂金英.头孢他啶与左氧氟沙星联用对心力衰竭伴肺部感染患者的临床疗效及其对心功能的影响[J].抗感染药学,2019,16(9):1628-1631.
|
[9] |
徐敬.左氧氟沙星联用头孢他啶对心力衰竭伴肺部感染患者的疗效分析[J].临床研究,2019,27(9):76-78.
|
[10] |
杨文静.头孢他啶与左氧氟沙星联用对心力衰竭伴肺部感染患者的疗效及其对细菌清除的影响[J].抗感染药学,2019,16(8):1402-1404.
|
[11] |
林凤萍,李成志,陈嘉惠.左氧氟沙星联合头孢他啶治疗脑卒中患者肺部感染的疗效观察[J].北方药学,2019,16(8):86-87.
|
[12] |
杨丽娟,梁云,韩志成.头孢他啶与左氧氟沙星联用对心力衰竭患者伴肺部感染的疗效及其对病原菌清除和炎症因子水平的影响[J].抗感染药学,2019,16(7):1224-1226.
|
[13] |
韩欣宇.头孢他啶联合左氧氟沙星治疗心力衰竭患者肺部感染的效果及对血清炎症因子的影响[J].齐齐哈尔医学院学报,2019,40(11):1344-1345.
|
[14] |
曾凡海.头孢他啶与左氧氟沙星联用对老年心力衰竭患者伴肺部感染的临床疗效及其对肺功能的影响[J].抗感染药学,2019,16(4):656-658.
|
[15] |
陈德生,符信萍.头孢他啶与左氧氟沙星联用对心力衰竭患者伴肺部感染的临床疗效评价[J].抗感染药学,2018,15(12):2122-2124.
|
[16] |
肖存志,周红香.头孢他啶与左氧氟沙星联用对心力衰竭患者伴肺部感染的临床疗效及其对炎症因子水平的影响[J].抗感染药学,2018,15(11):1872-1874.
|
[17] |
费超群.左氧氟沙星联合头孢他啶治疗尿路感染的临床疗效[J].药品评价,2018,15(15):30-32,35.
|
[18] |
邓先柱.头孢他啶与左氧氟沙星对心力衰竭患者伴肺部感染的临床疗效及其对炎症指标水平的影响[J].抗感染药学,2018,15(2):324-326.
|
[19] |
刘江.头孢他啶联合左氧氟沙星治疗心力衰竭患者肺部感染的临床效果观察[J].当代医学,2018,24(2):128-129.
|
[20] |
杨德恩.左氧氟沙星与头孢他啶联用对左心力衰竭患者伴肺部感染的临床疗效及其对心力衰竭指标的影响[J].抗感染药学,2017,14(7):1431-1433.
|
[21] |
肇丁.左氧氟沙星联合头孢他啶治疗尿路感染的临床疗效观察[J].中国药物经济学,2017,12(9):111-113.
|
[22] |
袁永立.头孢他啶与左氧氟沙星联用对心力衰竭伴肺部感染患者的疗效及其对炎症因子及脑钠肽水平的影响[J].抗感染药学,2017,14(5):1075-1077.
|
[23] |
肖海凤.头孢他啶联合左氧氟沙星治疗老年心力衰竭合并肺部感染的效果及对血清WBC、PCT 的影响[J].中国医学创新,2021,18(16):43-46.
|
[24] |
于文建.左氧氟沙星与头孢他啶联用对晚期泌尿系统肿瘤伴感染患者的临床疗效评价[J].抗感染药学,2017,14(2):422-423.
|
|
|
|